Medical comorbidities in patients with chronic lymphocytic leukaemia treated with idelalisib: analysis of two large randomised clinical trials
Author:
Affiliation:
1. Oregon Health and Science University Portland OR USA
2. Gilead Sciences Foster City CA USA
3. City of Hope National Medical Center Duarte CA USA
Funder
Leukemia and Lymphoma Society
Publisher
Wiley
Subject
Hematology
Link
https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16879
Reference40 articles.
1. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia
2. Interactions between comorbidity and treatment of chronic lymphocytic leukemia: results of German Chronic Lymphocytic Leukemia Study Group trials
3. In CLL, comorbidities and the complex karyotype are associated with an inferior outcome independently of CLL-IPI
4. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial
5. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
Cited by 18 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Optimization of mHealth behavioral interventions for patients with chronic lymphocytic leukemia: the HEALTH4CLL study;J CANCER SURVIV;2024
2. Gene targeted and immune therapies for nodal and gastrointestinal follicular lymphomas;World Journal of Gastroenterology;2023-12-28
3. Recent advances in treatment of nodal and gastrointestinal follicular lymphoma;World Journal of Gastroenterology;2023-06-21
4. A novel comorbidity score for older adults with non-Hodgkin lymphoma: the 3-factor risk estimate scale;Blood Advances;2023-06-13
5. Idelalisib plus rituximab versus ibrutinib in the treatment of relapsed/refractory chronic lymphocytic leukaemia: A real‐world analysis from the Chronic Lymphocytic Leukemia Patients Registry (CLLEAR);British Journal of Haematology;2023-03-27
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3